Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERLL: Pentostatin, Cyclophosphamide, and Rituximab in Indolent B-Cell Lymphomas
NCT00927797Phase 2Unknown
- Sponsor
- Heidelberg University
- Start
- Feb 2005
- Primary completion
- Jan 2009
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
A Phase 2 trial of pentostatin, cyclophosphamide, rituximab in Waldenström macroglobulinemia (WM), chronic lymphocytic leukemia (CLL), Indolent B-cell lymphoma (iBCL), sponsored by Heidelberg University. Status: unknown.
02
Drugs
pentostatincyclophosphamiderituximab
03
Conditions
Waldenström macroglobulinemia (WM)chronic lymphocytic leukemia (CLL)Indolent B-cell lymphoma (iBCL)
Beyond the preview
Go deeper on NCT00927797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00927797.